Kane B.; Rapid Testing for HIV: Why So Fast?. Ann Intern Med. 1999;131:481-483. doi: 10.7326/0003-4819-131-6-199909210-00101
Download citation file:
Published: Ann Intern Med. 1999;131(6):481-483.
Only one rapid test for diagnosing HIV infection is currently approved by the U.S. Food and Drug Administration (FDA). The screening enzyme immunoassay marketed as a single use diagnostic system (SUDS) by Abbott Diagnostics (Abbott Park, lllinois)—is a multistep test that gives a colorimetric reading within 10 to 15 minutes of adding two drops of a patient's serum or plasma to the test kit's cartridge. When this test was first approved by the FDA in 1992, the U.S. Public Health Service did not trumpet the benefits of rapid HIV testing. Instead, it continued supporting its 1989 recommendations that advised health care providers to withhold unconfirmed positive results of HIV tests. Many states embraced these recommendations as law, mandating that initially positive results obtained from screening tests be confirmed by Western blot or enzyme-linked immunofluorescence assay (ELISA) before tested persons could be notified.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, HIV, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only